798 results on '"Schoser, Benedikt"'
Search Results
2. Validation of the German version of the SarQoL® questionnaire in sarcopenic and probable sarcopenic patients
3. Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy
4. Author Correction: Degeneration of muscle spindles in a murine model of Pompe disease
5. Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease
6. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)
7. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
8. Multi-level profiling unravels mitochondrial dysfunction in myotonic dystrophy type 2
9. 11-beta-hydroxysteroid dehydrogenase type 1 (HSD11B1) gene expression in muscle is linked to reduced skeletal muscle index in sarcopenic patients
10. Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis
11. Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis
12. Evaluation of myotonometry for myotonia, muscle stiffness and elasticity in neuromuscular disorders
13. Morphological and molecular comparison of HIV-associated and sporadic inclusion body myositis
14. Correction to: Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP‑mediated disease reveals characteristic features useful for diagnosis
15. Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review
16. Frequency and satisfaction of conventional and complementary or alternative therapies for neuromuscular disorders
17. Degeneration of muscle spindles in a murine model of Pompe disease
18. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial
19. Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial
20. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
21. Efficacy of functional electrical stimulation in rehabilitating patients with foot drop symptoms after stroke and its correlation with somatosensory evoked potentials—a crossover randomised controlled trial
22. Suitability of the Respicheck questionnaire and Epworth sleepiness scale for therapy monitoring in myotonic dystrophy type 1
23. Nociceptive pain in adult patients with 5q-spinal muscular atrophy type 3: a cross-sectional clinical study
24. Prediction of respiratory impairment in myotonic dystrophies using the ‘Respiratory involvement symptom checklist’ (Respicheck)
25. Editorial: Framing artificial intelligence to neuromuscular disorders
26. The current clinical perception of myotonic dystrophy type 2
27. Exploration of mitochondrial defects in sarcopenic hip fracture patients
28. BNIP3 Is Involved in Muscle Fiber Atrophy in Late-Onset Pompe Disease Patients
29. Small fiber involvement is independent from clinical pain in late-onset Pompe disease
30. Validation of the German version of the SarQoL® questionnaire in sarcopenic and probable sarcopenic patients.
31. Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease.
32. Nociceptive Pain in Patients with Neuromuscular Disorders: A Cross-Sectional Clinical Study.
33. Start, switch and stop (triple‐S) criteria for enzyme replacement therapy of late‐onset Pompe disease: European Pompe Consortium recommendation update 2024.
34. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
35. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
36. The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
37. STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
38. Improving outcome measures in late onset Pompe disease: Modified Rasch‐Built Pompe‐Specific Activity scale.
39. Non-dystrophic myotonias: clinical and mutation spectrum of 70 German patients
40. Characterization of the neuropathic pain component contributing to myalgia in patients with myotonic dystrophy type 1 and 2.
41. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
42. Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia
43. Influence of IGF-I serum concentration on muscular regeneration capacity in patients with sarcopenia
44. A systematic review on the definition of rhabdomyolysis
45. A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients
46. A Systematic Review of the Health Economics of Pompe Disease
47. Meta-analysis towards FSHD reveals misregulation of neuromuscular junction, nuclear envelope, and spliceosome.
48. Therapeutic resistance training: proposal for an algorithm-based approach.
49. The 2022 European postgraduate (residency) programme in neurology in a historical and international perspective.
50. Editorial: Modern Gestalt approach to neuromuscular disorders: time for a precision Gestalt
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.